Market Overview

Myriad Says myPath Melanoma Test Highly Effective in Verification Study

Related MYGN
Top 4 Stocks In The Research Services Industry With The Highest Revenue
Myriad's Downside Case Might Not Matter
LabCorp (LH) Poised to Outshine Q1 Earnings Estimates - Analyst Blog (Zacks)

Myriad Genetics, Inc. (Nasdaq: MYGN) today announced that results from a verification study showed the Myriad myPath™ Melanoma test effectively differentiated malignant melanoma from benign skin lesions. The clinically-actionable information provided by myPath Melanoma will empower healthcare providers with objective data and improve the diagnosis of patients with melanoma. Myriad presented these data at the American Society of Dermatopathology Annual Meeting on Oct. 13, 2013.

The verification study evaluated a 23-gene panel designed to differentiate malignant melanoma from benign skin lesions. The study analyzed 464 skin biopsy samples including 254 samples representing melanomas from all major subtypes including superficial spreading, lentigo maligna melanoma, acral, nodular and desmoplastic lesions. Using this set of patient samples, the myPath Melanoma test demonstrated high sensitivity of 89 percent and specificity of 93 percent at differentiating malignant melanoma from benign skin lesions.

Posted-In: News FDA


Related Articles (MYGN)

Around the Web, We're Loving...